Ata uhi

Inhibition of inflammatory liver injury by the HMGB1-A box through HMGB1/TLR-4/NF-κB signaling in an acute liver failure mouse model

We aimed to investigate the preventive effect of high mobility group box 1 (HMGB1)-A box and the mechanism by which it alleviates inflammatory injury in acute liver failure (ALF) by inhibiting the extracellular release of HMGB1. BALB/c mice were intraperitoneally (i.p.) administered LPS/D-GalN to es...

Whakaahuatanga katoa

I tiakina i:

Ngā taipitopito rārangi puna kōrero
Ngā kaituhi matua:	Lidan Luo (Author), Shuai Wang (Author), Bohao Chen (Author), Mei Zhong (Author), Ruili Du (Author), ChunShan Wei (Author), Furong Huang (Author), Xinhui Kou (Author), Yufeng Xing (Author), Guangdong Tong (Author)
Hōputu:	Pukapuka
I whakaputaina:	Frontiers Media S.A., 2022-10-01T00:00:00Z.
Ngā marau:	article
Urunga tuihono:	Connect to this object online.
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!

Ngā tūemi rite

Isochlorogenic Acid A Attenuates the Progression of Liver Fibrosis Through Regulating HMGB1/TLR4/NF-κB Signaling Pathway
mā: Xin Liu, me ētahi atu.
I whakaputaina: (2020)

Emerging Role of High-Mobility Group Box 1 (HMGB1) in Liver Diseases
mā: Ruochan Chen, me ētahi atu.
I whakaputaina: (2013)

Inhibition of HMGB1/RAGE-mediated endocytosis by HMGB1 antagonist box A, anti-HMGB1 antibodies, and cholinergic agonists suppresses inflammation
mā: Huan Yang, me ētahi atu.
I whakaputaina: (2019)

Aucubin Attenuates Liver Ischemia-Reperfusion Injury by Inhibiting the HMGB1/TLR-4/NF-κB Signaling Pathway, Oxidative Stress, and Apoptosis
mā: Shilong Zhang, me ētahi atu.
I whakaputaina: (2020)

Aloperine Ameliorates Acetaminophen-Induced Acute Liver Injury through HMGB1/TLR4/NF-κB and NLRP3/Inflammasome Pathway
mā: Hui Chen, me ētahi atu.
I whakaputaina: (2024)

Potential regulatory role of the Nrf2/HMGB1/TLR4/NF-κB signaling pathway in lupus nephritis
mā: Shi-jie Li, me ētahi atu.
I whakaputaina: (2023)

Saquinavir Ameliorates Liver Warm Ischemia-Reperfusion-Induced Lung Injury via HMGB-1- and P38/JNK-Mediated TLR-4-Dependent Signaling Pathways
mā: Zhuang Yu, me ētahi atu.
I whakaputaina: (2017)

Synthesized HMGB1 peptide attenuates liver inflammation and suppresses fibrosis in mice
mā: Shunsuke Nojiri, me ētahi atu.
I whakaputaina: (2021)

The role of high mobility group box 1 (HMGB1) in the pathogenesis of kidney diseases
mā: Qingjie Chen, me ētahi atu.
I whakaputaina: (2016)

Evodiamine protects against airway remodelling and inflammation in asthmatic rats by modulating the HMGB1/NF-κB/TLR-4 signalling pathway
mā: Qiong Wang, me ētahi atu.
I whakaputaina: (2021)

Huang Qi Tong Bi Decoction Attenuates Myocardial Ischemia-Reperfusion Injury via HMGB1/TLR/NF-κB Pathway
mā: Kun Liu, me ētahi atu.
I whakaputaina: (2019)

The Role of HMGB1 in Immunity
I whakaputaina: (2020)

Catalpol Protects Against Spinal Cord Injury in Mice Through Regulating MicroRNA-142-Mediated HMGB1/TLR4/NF-κB Signaling Pathway
mā: Hougang Xia, me ētahi atu.
I whakaputaina: (2021)

HMGB1/TLR4 Signaling Affects Regulatory T Cells in Acute Lung Injury
mā: Zhou M, me ētahi atu.
I whakaputaina: (2021)

Oxymatrine Attenuates Dopaminergic Neuronal Damage and Microglia-Mediated Neuroinflammation Through Cathepsin D-Dependent HMGB1/TLR4/NF-κB Pathway in Parkinson's Disease
mā: Ping Gan, me ētahi atu.
I whakaputaina: (2020)

Baiying qingmai formulation ameliorates thromboangiitis obliterans by inhibiting HMGB1/RAGE/NF-κB signaling pathways
mā: Chongchong Zou, me ētahi atu.
I whakaputaina: (2022)

Amentoflavone attenuates oxidative stress and neuroinflammation induced by cerebral ischemia/reperfusion in rats by targeting HMGB1-mediated TLR4/NF-κB signaling pathway
mā: Abdulaziz S. Saeedan, me ētahi atu.
I whakaputaina: (2023)

Prunella vulgaris L. Attenuates Experimental Autoimmune Thyroiditis by Inhibiting HMGB1/TLR9 Signaling
mā: Guo Q, me ētahi atu.
I whakaputaina: (2021)

CGA mitigates HMGB1 mediated TLR4 activated hepatic cancer in urethane primed mice
mā: Alok Tripathi, me ētahi atu.
I whakaputaina: (2024)

Berberine Ameliorates Subarachnoid Hemorrhage Injury via Induction of Sirtuin 1 and Inhibiting HMGB1/Nf-κB Pathway
mā: Xiang-Hua Zhang, me ētahi atu.
I whakaputaina: (2020)

HMGB1 and Extracellular Histones Significantly Contribute to Systemic Inflammation and Multiple Organ Failure in Acute Liver Failure
mā: Runkuan Yang, me ētahi atu.
I whakaputaina: (2017)

Analysis of glycyrrhizin binding to protein HMGB1
mā: Gérard Vergoten, me ētahi atu.
I whakaputaina: (2020)

HMGB1 Localization during Experimental Periodontitis
mā: Andressa Vilas Boas Nogueira, me ētahi atu.
I whakaputaina: (2014)

Increased Serum Concentrations of High Mobility Group Box 1 (HMGB1) Protein in Children with Autism Spectrum Disorder
mā: Gerasimos Makris, me ētahi atu.
I whakaputaina: (2021)

Compound amino acid combined with high-dose vitamin B6 attenuate traumatic coagulopathy via inhibiting inflammation by HMGB1/TLR4/NF-κB pathway
mā: Shi-Jian Yi, me ētahi atu.
I whakaputaina: (2020)

Sevoflurane Postconditioning Attenuates Hepatic Ischemia-Reperfusion Injury by Limiting HMGB1/TLR4/NF-κB Pathway via Modulating microRNA-142 in vivo and in vitro
mā: Liying Xu, me ētahi atu.
I whakaputaina: (2021)

Peripheral HMGB1-induced hyperalgesia in mice: Redox state-dependent distinct roles of RAGE and TLR4
mā: Daichi Yamasoba, me ētahi atu.
I whakaputaina: (2016)

Ligation of free HMGB1 to TLR2 in the absence of ligand is negatively regulated by the C-terminal tail domain
mā: Hannah Aucott, me ētahi atu.
I whakaputaina: (2018)

Exploring the biological functional mechanism of the HMGB1/TLR4/MD-2 complex by surface plasmon resonance
mā: Mingzhu He, me ētahi atu.
I whakaputaina: (2018)

Sesamin attenuates intestinal injury in sepsis via the HMGB1/TLR4/IL-33 signalling pathway
mā: Zhi-Ling Li, me ētahi atu.
I whakaputaina: (2020)

HMGB1-Induced Hepatocyte Pyroptosis Expanding Inflammatory Responses Contributes to the Pathogenesis of Acute-on-Chronic Liver Failure (ACLF)
mā: Hou W, me ētahi atu.
I whakaputaina: (2021)

Retraction Note to: Redox modification of cysteine residues regulates the cytokine activity of high mobility group box-1 (HMGB1)
mā: Huan Yang, me ētahi atu.
I whakaputaina: (2020)

Expression of Concern to: Redox modification of cysteine residues regulates the cytokine activity of high mobility group box-1 (HMGB1)
mā: Huan Yang, me ētahi atu.
I whakaputaina: (2020)

The Comprehensive Role of High Mobility Group Box 1 (HMGB1) Protein in Different Tumors: A Pan-Cancer Analysis
mā: Guan H, me ētahi atu.
I whakaputaina: (2023)

Research on the interaction of astragaloside IV and calycosin in Astragalus membranaceus with HMGB1
mā: Junyi Ye, me ētahi atu.
I whakaputaina: (2023)

HMGB1-RAGE signaling pathway in pPROM
mā: Huan Yan, me ētahi atu.
I whakaputaina: (2018)

Pharmacological Inhibition of HMGB1 Prevents Muscle Wasting
mā: Lu Li, me ētahi atu.
I whakaputaina: (2021)

Ma Xing Shi Gan Decoction Attenuates PM2.5 Induced Lung Injury via Inhibiting HMGB1/TLR4/NFκB Signal Pathway in Rat
mā: Yu-xiang Fei, me ētahi atu.
I whakaputaina: (2019)

Correction to: Exploring the biological functional mechanism of the HMGB1/TLR4/MD-2 complex by surface plasmon resonance
mā: Mingzhu He, me ētahi atu.
I whakaputaina: (2018)

Carbenoxolone Blocks Endotoxin-Induced Protein Kinase R (PKR) Activation and High Mobility Group Box 1 (HMGB1) Release
mā: Wei Li, me ētahi atu.
I whakaputaina: (2013)